A mouse pituitary tumor cell line (AtT-20) releases corticotropin (ACTH) in response to a number of secretagogues, iWciuding corticotropin-releasing factor (CRF), j3-adrenergic aints, N6,02'-dibutyryladenosine 3',5'-cyclic monophosphate (Bt2 cAMP), and potassium. The AtT-20 mouse pituitary cell line is a well-characterized model system to study corticotropin (ACTH) secretion. These cells release ACTH in response to a number of secretagogues, including corticotropin-releasing factor (CRF), isoproterenol, vasoactive intestinal peptide, the Ca2+ ionophore A23187, and potassium (1). It has been shown that the second messengers cAMP and Ca2+ (1), as well as phospholipid methylation (2), are involved in the mediation of these secretory responses. There has also been indirect evidence suggesting that arachidonic acid and/or its metabolites may be involved in ACTH secretion in AtT-20 cells. Phorbol esters and melittin, activators of phospholipase A2 (3-7), the enzyme that liberates arachidonic acid from lipids, are potent stimulators of ACTH secretion (8, 9). The synthetic corticosterone dexamethasone, which exerts some of its actions by inhibiting phospholipase A2 (10), blocks ACTH release (1). These findings prompted an investigation as to whether arachidonic acid or one or more of its many metabolites are involved in receptor-mediated ACTH secretion.
The AtT-20 mouse pituitary cell line is a well-characterized model system to study corticotropin (ACTH) secretion. These cells release ACTH in response to a number of secretagogues, including corticotropin-releasing factor (CRF), isoproterenol, vasoactive intestinal peptide, the Ca2+ ionophore A23187, and potassium (1) . It has been shown that the second messengers cAMP and Ca2+ (1) , as well as phospholipid methylation (2) , are involved in the mediation of these secretory responses. There has also been indirect evidence suggesting that arachidonic acid and/or its metabolites may be involved in ACTH secretion in AtT-20 cells. Phorbol esters and melittin, activators of phospholipase A2 (3) (4) (5) (6) (7) , the enzyme that liberates arachidonic acid from lipids, are potent stimulators of ACTH secretion (8, 9) . The synthetic corticosterone dexamethasone, which exerts some of its actions by inhibiting phospholipase A2 (10) , blocks ACTH release (1) . These findings prompted an investigation as to whether arachidonic acid or one or more of its many metabolites are involved in receptor-mediated ACTH secretion.
Arachidonic acid is metabolized via three pathways: cycloxygenase, which generates prostaglandins and tromboxanes, lipoxygenase, which forms leukotrienes, and the NADPH-dependent cytochrome P-450 enzymes (epoxygenase), which forms epoxide metabolites (11) . To ascertain whether metabolites of these pathways are involved in ACTH release, inhibitors of each of these enzymes as well as phospholipase A2 were used. We find that inhibitors of phospholipase A2, lipoxygenase, and epoxygenase, but not cycloxygenase, block the release of ACTH in AtT-20 cells.
MATERIALS AND METHODS
Synthetic CRF was obtained from Bachem Fine Chemicals (Torrance, CA), (-)-isoproterenol (+)-bitartrate, human serum albumin, 3-isobutyl-1-methylx4thine (IBMX), melittin, phorbol myristate acetate, nordihydrbguaieretic acid, butylated hydroxytoluene, p-bromophenacyl-bromide, mepacrine, A23187, N6,02'-dibutyryladenosine 3',5'-cyclic monophosphate (Bt2cAMP), 8-bromoadenosine 3',5'-cyclic monophosphate (8-Br-cAMP), and barbital were from Sigma. Forskolin was purchased from Calbiochem-Behring. Icosatetraynoic acid was kindly supplied by F. Hirata. Piperonyl butoxide and 2-diethylaminoethyl-2,2-diphenylvalerate (SKF 525A) were a generous gift from J. Gillette.
Cell Culture Methods. AtT-20/D16-16 cells were grown and subcultured in Dulbecco's modified Eagle's medium (DME medium) with 10% calf serum, as described (12) . Cells were plated in 30-mm (diameter) culture dishes at an initial density of 1.5 x 105 cells per well and were used 5-6 days after plating (60-80% confluency). For ACTH secretion studies, cells were equilibrated for 30 min at 37°C in 1 ml of DME medium/25 mM Hepes, pH 7.4, containing bovine serum albumin at 1 mg/ml (preincubation). The medium was then aspirated and replaced with 1 ml of the same medium containing the compounds to be tested, and the cells were incubated for 60 min. An aliqilot of the medium was centrifuged and the supernatant solution was frozen at -20°C until used for ACTH assay. For cAMP studies, the preincubation was carried out in the presence of 0.5 mM IBMX for 30 min. This medium was then replaced with 1 ml of fresh medium containing 0.5 mM IBMX and the test compounds. After 15 min the medium was aspirated and 1 ml of ice-cold ethanol was added to the cells and left overnight at 0-4°C. A 0.1-ml aliquot was dried under vacuum and resuspended in 0.1 ml of 50 mM sodium acetate buffer at pH 6.2 for cAMP measurements.
For experiments in which (-)-isoproterenol was used, 10 ,uM ascorbic acid was added to the medium. Melittin was prepared in acidified phosphate-buffered saline and 1% bovine serum albumin at 2 mg/ml. A23187 was dissolved in dimethyl sulfoxide at 5 mg/ml. Dibutyryl Bt2cAMP, 8-BrcAMP, IBMX, and p-bromophenacylbromide were dissolved before each experiment in the medium at the final concentration. All other agents were added from 1000x concentrated solutions in ethanol. Ethanol and dimethyl sulfoxide did not have any effect on ACTH secretion and cAMP synthesis at the concentrations used in these studies.
ACTH and cAMP Assays. ACTH immunoreactivity was assayed in the medium as described (12) by using an antiserum specific for the 14-24 region of ACTH. cAMP levels were determined with the assay kit from New England Nuclear.
Abbreviations: ACTH, corticotropin; CRF, corticotropin-releasing factor; IBMX, 3-isobutyl-1-methylxanthine; 8-Br-cAMP, 8-bromoadenosine 3',5'-cyclic monophosphate; Bt2cAMP, N6,02'-dibutyryladenosine 3',5'-cyclic monophosphate.
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RESULTS
The effects of phospholipase A2 and cycloxygenase blockers on the ACTH release induced by CRF in AtT-20 were first examined (Fig. 1) . The phospholipase A2 blockers mepacrine and p-bromophenacylbromide (13-17) suppressed the CRF-induced ACTH release, whereas the cycloxygenase inhibitor indomethacin had no effect (Fig. 2) . The lipoxygenase inhibitors nordihydroguaieretic acid and butylated hydroxytoluene (18) (19) (20) suppressed the receptor-mediated ACTH secretion (Fig. 2) . Icosatetraynoic acid, an inhibitor of both cycloxygenase and lipoxygenases (21) , also reduced CRF-induced release of ACTH (Fig. 2) .
Potent blockers of ACTfI release were SKF 525A and piperonyl butoxide, inhibitors of the cytochrome P-450 monoxygenases (22) (Fig. 3) , whereas metyrapone, a blocker of some forms of this enzyme (22) , was ineffective. When isoproterenol was used to induce ACTH secretion, the effects of the enzyme inhibitors were similar to those described above with CRF (data not shown). The basal ACTH release was decreased only slightly and inconsistently by nordihydroguaieretic acid, butylated hydroxytoluene, and SKF 525A.
Both CRF and isoproterenol increase ACTH secretion in AtT-20 cells by stimulating cAMP synthesis (1). To examine whether these inhibitors act at the level of cAMP formation, their effect on the generation of this second messenger induced by CRF was studied. The compounds tested-namely, nordihydroguaieretic acid, SKF 525A, piperonyl butoxide, p-bromophenacylbromide, and mepacrine-had no effect on cAMP formation by CRF at concentrations that blocked 90% of the stimulated ACTH release. An exception was mepacrine, which reduced both the basal and the CRFinduced cAMP generation by 50%. SKF 525A was also examined for its effects on secretagogues that bypass the adenylate cyclase system, such as potassium, 8-Br-cAMP, Bt2cAMP, and the Ca2+ ionophore A23187 (1). The ACTH-releasing action of potassium and the two cAMP analogs was markedly reduced, whereas the release of ACTH induced by compound A23187 was not prevented. Forskolin, an activator of the cyclase activity and stimulator of ACTH (9) release, was inhibited by SKF 525A. The use of piperonyl butoxide and nordihydroguaieretic acid produced results similar to those obtained with SKF 525A (Table 1 ). The phospholipase A2 blockers mepacrine and pbromophenacylbromide (both at 100 kLM) also failed to reduce the stimulation of ACTH release caused by the ionophore A23187 (data not shown).
DISCUSSION
The results described in this report suggest that the release of ACTH in AtT-20 cells involves metabolic products formed from arachidonic acid through the NADPH-dependent cytochrome P-450 and/or the lipoxygenase pathways. Cycloxygenase metabolites do not appear to be linked to ACTH release. The participation of arachidonic acid in the secretion of ACTH is suggested by the suppression of release of the peptide by the two phospholipase A2 inhibitors mepacrine and p-bromophenacylbromide at concentrations similar to those reported to block phospholipase A2 activity (13) (14) (15) (16) (17) . It is unlikely that arachidonic acid is the agent directly concerned with ACTH release. It is more likely that it might serve as a substrate for the formation of one or more metabolic products active in the release process. This is based on the observation that ACTH release is suppressed by blockers of arachidonic acid metabolism. Inhibition of lipoxygenase, the enzyme that generates leukotrienes and hydroxyicosatetraenoic acids from arachidonic acid, blocks stimulated ACTH release.
A recently discovered pathway for arachidonic acid metabolism is the NADPH-dependent cytochrome P-450 epoxygenase (11) . Inhibitors of cytochrome P-450, piperonyl butoxide, and SKF 525A, compounds of dissimilar structure, blocked the stimulated ACTH release at relatively low concentrations in a dose-dependent manner. Lipoxygenase and epoxygenase inhibitors reduced ACTH release at concentrations similar to those reported to inhibit the lipoxygenase and the cytochrome P-450 epoxygenase enzymes, respectively (18) (19) (20) (21) (22) (23) . The epoxygenase can also be effectively blocked by the three lipoxygenase inhibitors used in this study (22, 23) . These findings implicate epoxygenase products ip the secretion of ACTH in AtT-20 cells. Consistent with this suggestion is the preliminary evidence obtained by high-pressure liquid chromatography that the epoxygenase metabolites of arachidonic acid occur in the AtT-20 cells.
Cytochrome P-450 enzymes are highly localized in the liver microsomes and are involved in the metabolism of drugs and other foreign compounds as well as steroids (24) . They are also present to a smaller extent in other tissues, including the brain (25) . Arachidonic acid is also a substrate for this enzyme (11) and it has been shown that some of its metabolites possess biological activity in secretory systems (23, 26) .
The cytochrome P-450 enzyme has been extensively studied and a great deal is known about its many forms, their properties, and their numerous substrates and inhibitors. In addition, cytochrome P-450 isozymes can be differentially induced by specific substrates (27) . This knowledge could be used to study the characteristics of the isozyme involved in ACTH secretion and to manipulate its activity selectively.
There are several steps of the secretion process in which arachidonic acid metabolites could be involved. Previous work has shown that stimulation 'of ACTH release in AtT-20 cells by CRF and other hormones is mediated by cAMP generation and Ca2' entry as well as by phospholipid methylation (2) . The activation of the adenylate cyclase by CRF is not blocked by the inhibitors of arachidonic acid metabolism examined in this study. This indicates that the metabolites required for release are involved in a step distal to cAMP formation. It also demonstrates a degree of selectivity in the action of these inhibitors.
The inhibitors that block CRF-stimulated ACTH release also prevent the release induced by agents that bypass the adenylate cyclase system, such as potassium and Bt2cAMP. The only secretagogue whose action is not blocked by the above inhibitors is the Ca2+ ionophore A23187, which bypasses the cellular mechanisms regulating cytosolic Ca2 . This would suggest that the arachidonic acid metabolites concerned with the ACTH release are involved in the increase in cystolic Ca2+ induced by the secretagogues.
